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Abstract. A Mexican family with partial congenital nephrogenic
diabetes insipidus (NDI) that resulted from a mutation in the aqua-
porin-2 water channel (AQP2) was characterized, and the source of
this rare mutation was traced to the family’s town of origin in
Mexico. Affected individuals with profound polyuria and polydipsia
were homozygous for an autosomal recessive missense V168M mu-
tation in the AQP2 gene. Expression in oocytes revealed that, al-
though retained in the endoplasmic reticulum (ER) to a great extent,
a considerable amount of the partially functional AQP2-V168M was
expressed at the plasma membrane, and that its ER retention was less
than AQP2-T126M, a functional mutant in severe recessive NDI.
None of the affected AQP2-V168M individuals had neurologic def-
icits, which also suggested a milder form of the disease. The homozy-
gous individuals reported subjective improvement in polyuria and
polydipsia with the use of dDAVP (1-desamino-8-D-arginine-vaso-
pressin). When clinically tested, infusion of dDAVP at variable doses
produced a partial increase in the urinary osmolality in homozygous
individuals and decreased their water intake. Heterozygotes were
unaffected when compared with controls. Samples were obtained
from the population of the Mexican town of origin of the family; 30%
of the population was heterozygous for the V168M AQP2 mutation
and 1% was homozygous for the mutation. The high frequency of
this rare mutation in the town provides evidence for an important
health care problem in the village with consequences for future
generations.
Diabetes insipidus is defined by a 24-h urine volume greater
than 3 L and urinary osmolality less than 300 mOsm/kg (1).
Diabetes insipidus can be of central or nephrogenic origin, and
it can be acquired or hereditary. Individuals affected with
nephrogenic diabetes insipidus (NDI) are prone to severe de-
hydration if unable to access liquids and can experience failure
to thrive, mental retardation, and death early in life (2–5).
Adequate intake of water allows a normal lifespan and good
physical and mental development (6).
Inherited NDI results from mutations in two different genes;
90% occur in the gene that codes for the vasopressin 2 receptor
(AVPR2) found on the X chromosome (7) and 10% in the gene for
aquaporin-2 (AQP2) (8). The aquaporin membrane pore is located
in the collecting duct cells and is the primary target by which
vasopressin regulates permeability of water. AQP2 (xm_006751)
is located on chromosome 12q13, consists of four exons and
encodes a 271–amino acid protein with six transmembrane do-
mains. Thirty mutations in AQP2 have been reported, most com-
monly recessive missense mutations that cause misfolding of the
protein and retention in the endoplasmic reticulum (ER) (3,4,9–
16). Dominant mutations are less common and are characterized
by retention of AQP2 in the Golgi complex region, late endo-
somes/lysosomes, or basolateral membrane due to the formation
of heterotetramers of normal and abnormal AQP2 (17–21).
We have identified a family from Mexico with familial NDI
caused by a recessive mutation in the AQP2 gene. The mutant
aquaporin-2 is partially functional in Xenopus oocytes. Af-
fected family members reported improvement in thirst and
urination with the use of nasal and oral dDAVP (1-desamino-
8-D-arginine-vasopressin), prompting the study of the clinical
differences between homozygous, heterozygous and controls.
Finally, a genetic epidemiologic study was performed in the
town of origin of the family in Mexico.
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Materials and Methods
Water Deprivation Tests
The study was approved by the Institutional Review Board of the
University of Texas Health Science Center at Houston. Written in-
formed consent was obtained from the family members that partici-
pated in the genetic and clinical studies, and verbal informed consent
was obtained from the townspeople in the genetic epidemiologic study
done in Mexico. Clinical studies were done at the Clinical Research
Center of The University of Texas Health Science Center at Houston.
dDAVP was stopped 24 h before any testing. Baseline 24-h urine
collections were performed to measure volume and urine osmolality.
The technique used for the water deprivation test has been previously
described (22,23). Baseline samples for urine osmolality (Uosm),
serum osmolality (Sosm), serum electrolytes, and plasma arginine
vasopressin (AVP) were taken. AVP samples were collected in hep-
arinized plasma and immediately frozen for future processing. Hyper-
tonicity was initiated with a continuous 3% saline infusion at a rate of
0.06 ml/kg/min. Sosm was checked hourly until a level of 300
mOsm/kg was reached. Then, a second plasma sample for AVP was
obtained before 1 g of dDAVP was provided intravenously to each
subject. Urine volume, Uosm, and Sosm were monitored hourly for
the next 2 h.
dDAVP Challenge Test
Controls and homozygous and heterozygous family members un-
derwent a dDAVP challenge test with water restriction as a surrogate
for a full water deprivation test (24–27). Fluid intake was limited to
250 ml/h. Baseline samples for Uosm, Sosm, serum electrolytes,
blood urea nitrogen, glucose, creatinine, and calcium were obtained.
Urinary volume and fluid intake were monitored hourly. Uosm was
checked 3 h after each dose of dDAVP to ascertain maximal effect of
the drug (24–28). No further doses of dDAVP were provided when
Uosm was above 800 mOsm/kg (22,24,29). All of the dDAVP doses
were provided intravenously. The first dose of dDAVP consisted in 1
g for controls and heterozygotes and 5 g for homozygotes. Three
hours later, those with Uosm below 800 mOsm/kg received a second
dose of dDAVP, 4 g for the heterozygotes and controls and 0.4
g/kg for the homozygotes. Uosm was checked 3 h later.
Mutational Analysis
Genomic DNA from the family members was isolated from pe-
ripheral blood samples in adults and from buccal samples in children.
The DNA was extracted with the Pure Gene genomic DNA isolation
kit (Gentra Systems). Intron-based primers were used to PCR-amplify
the four exons of AQP2 (10). PCR amplifications were carried out
with HotstarTaq DNA polymerase (Qiagen, Valencia, CA) in a two-
cycle amplification program to amplify the genomic DNA. The DNA
fragments were sequenced with ABI Big Dye terminator kit on an
ABI Prism 310 DNA Analyzer (Applied Biosystems, Foster City,
CA).
Generation of the Mutant AQP2 cDNA Construct
PCR techniques were used to introduce a G502A transversion in
human AQP2 cDNA, which was cloned into the plasmid pT7Ts-
AQP2. The forward primer, TGCCATGGCGTTTGGCTTGG, has a
NcoI restriction site at the 5' end. The reverse primer, 5'-ATGGATC-
CCAAGGAGGTGGCCCAGGGCCATAGAGAAGCC-3' has a
BamHI site at the 5' end. A G502A transition was introduced into the
middle of the reverse primer. PCR was performed by using the
plasmid pT7Ts-AQP2 as the template. The PCR product was digested
by NcoI and BamHI and inserted into the corresponding sites of
pT7Ts-AQP2. The G502A mutation of AQP2 was confirmed by
sequencing.
Oocyte Experiments
Linearization of the pT7Ts-AQP2 and pT7Ts-AQP2-V168M con-
structs, cRNA synthesis, preparation and injection of oocytes, cell
swelling assays, immunoblotting, and immunocytochemistry were
performed as described (30). The obtained water permeabilities were
expressed as means  SEM. Differences between groups were tested
by t test corrected by the Bonferroni multiple-comparisons procedure.
Differences were considered statistically significant for P  0.05. To
determine the functionality of AQP2 mutants in relation to wt-AQP2,
all immunoblot signals of AQP2 proteins in the plasma membrane of
oocytes were semiquantified by densitometric scanning and compared
with the signals of a twofold dilution series of wt-AQP2, which was
blotted in parallel.
Because the quality of cRNA preparations and injected amounts
show variation for different cRNAs, the expressed amounts of the
AQP2 proteins from determined cRNA amounts is not reliable. There-
fore, our analyses with AQP2-V168M focused on whether AQP2-
V168M is a functional water channel and if so, to what extent
compared with wt-AQP2. Also, we wanted to determine whether it is
retained the ER, and if so, whether its retention is different from
wt-AQP2 and from AQP2-T126M, another AQP2 mutant that confers
severe instead of partial NDI in patients. For these analyses, similar
protein expression levels are needed, which is much better controlled
in oocytes than in mammalian cells. For determination whether a
mutant is retained in the cell, the plasma membrane expression levels
have to be compared for those oocytes that show similar total mem-
brane expression levels because the level of plasma membrane ex-
pression goes up with increased expression levels.
In a second analysis, by comparing the water permeabilities con-
ferred by similar plasma membrane expression levels of different
aquaporins, one can estimate the single channel permeability. For this,
the different amounts of wt-AQP2 expressed in the plasma membrane
fraction of oocytes and the corresponding water permeability (Pf)
values were fitted to the exponential function y a[1 exp(bx)]
c, where y is Pf and x is the amount of protein in arbitrary units. The
amount of wt-AQP2 that would be necessary to obtain the Pf value
observed for the mutants was calculated from the equation. The ratio
of the amount of wt-AQP2 and mutant AQP2 for the Pf that had been
obtained for the mutant indicates the single channel water permeabil-
ity of the mutant in relation to wt-AQP2 in percentage.
Genetic Epidemiologic Data
Samples were collected from individuals in a town in Mexico.
Subjects were asked for voluntary participation at their homes or in
public areas with the aid of the local physician and nurse. Participants
were over 18 yr old, born in the town, and had at least one parent
native to the town. Only one sibling of each family was sampled.
Buccal cell samples were collected with the Scope mouthwash tech-
nique (31,32). The samples had no personal identifiers and were
stored at 4°C until processed. DNA was extracted and AQP2 mutation
in exon 2 was analyzed by direct sequencing. The genotype frequen-
cies observed were compared with those expected under the assump-
tion of random mating; a 2 test was used for deviation from Hardy-
Weinberg equilibrium.
Statistical Analyses
Comparison between water deprivation and dDAVP tests, age
groups in the population samples, and the percentage of permeability
1224 Journal of the American Society of Nephrology J Am Soc Nephrol 15: 1223–1231, 2004
of the mutant relative to wt-AQP2 was determined by t test (33).
Deviation from the Hardy-Weinberg equilibrium was evaluated with
the bootstrapping and permutation techniques available in the genetics
library as programmed in R (34).
Results
Clinical Description of the Mexican Family
The family studied was originally from a small town north-
east of Monterrey, Mexico (Figure 1). Both parents were born
in the same town but denied consanguinity. The town started as
a ranch founded in 1600s and consists of a larger central area
and six satellite communities that share the same ancestry. The
total population of the town was 2078, according to the Mex-
ican census from the year 2000 (35). Both parents of the
studied family had normal thirst and urination and were healthy
except for moderate hypertension in the father. The mother had
experienced no miscarriages, and none of her children had
died. The first four of their five children had polydipsia and
polyuria soon after birth, and all had normal physical and
mental development without other medical problems. At the
age of 20 yr, an affected sibling (III-5) had a severe hyper-
natremic episode during a cesarean section. After recovering
from the episode, she was treated with dDAVP and reported a
50% decrease in nocturnal thirst and urination. The index
patient, the fourth child of the family, approached the endo-
crinology clinic at the University of Texas Houston and was
the first one to be studied by our group. He worked as a
construction worker in the Houston area and was able to work
in hot climates without experiencing dehydration by drinking
large amounts of water. He also reported a decrease in noctur-
nal polydipsia and polyuria by 50% when treated with dDAVP.
Mutational Analysis
DNA from the proband was used to sequence the exons and
flanking intronic sequences of AQP2. A homozygous G to A
nucleotide alteration was found at the position 502 in exon 2,
leading to a valine to methionine alteration at amino acid 168
in the fifth transmembrane domain of the aquaporin-2 water
channel. Exon 2 was sequenced using DNA from all family
members. All of the affected family members were homozy-
gous for the mutation, and all other sequenced family members
were heterozygous, except the maternal grandmother who did
not carry the mutation (Figure 1). Analysis of DNA from 31
white and 29 Hispanic individuals obtained from the Houston
area failed to reveal the mutation. A C/T polymorphism im-
mediately adjacent to the mutation (position 501 in exon 2) was
identified in the Hispanic controls. The polymorphism did not
alter an amino acid, and the frequency of the polymorphism
was 14%.
Functional Analysis of AQP2-V168M
To determine the biologic basis for NDI in this family, the
V168M encoding mutation was introduced in the human AQP2
cDNA contained in an oocyte expression vector, the cRNA
was transcribed and then injected into oocytes. cRNA coding
for AQP2-T126M, a functional mutant in recessive NDI (14),
was taken along. Determination of the water permeability (Pf)
of noninjected control and cRNA-injected oocytes revealed
that oocytes expressing AQP2-V168M had a significantly
higher Pf than control oocytes, indicating that AQP2-V168M is
a functional water channel (Figure 2). At the dosages used
here, AQP2-T126M did not confer any water permeability, but
at high expression levels, AQP2-T126M has shown to be a
functional water channel (14,36,37).
Because the quality of produced cRNA and the injected
amounts can vary, total membranes of these oocytes were
immunoblotted for AQP2 to reveal their expression levels
(Figure 3). At moderate expression levels, AQP2-V168M and
Figure 1. Pedigree of the Mexican family. Darkened symbols indicate
individuals with nephrogenic diabetes insipidus (NDI) and the pro-
band is indicated with an arrow. The amino acid alteration in the
aquaporin-2 (AQP2) protein is indicated below the symbol. V, valine
(wild-type sequence); M, methionine (mutant sequence). Individuals
marked M/M were affected, and individuals marked V/V or V/M
(heterzygotes) were unaffected.
Figure 2. Osmotic water permeability of oocytes expressing aqua-
porin-2 (AQP2)–V168M. Oocytes were not injected (c) or were
injected with the indicated amounts (ng) of cRNAs encoding wild-
type AQP2 (WT-AQP2), AQP2-V168M, or AQP2-T126M. Two days
after injection, the mean water permeabilities (Pf  SEM in m/s; n
 12) were determined in a standard swelling assay. Significant
differences between samples (P  0.05) are indicated by asterisks.
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AQP2-T126M were expressed as 29 kD nonglycosylated and
32 kD high-mannose glycosylated proteins (Figure 3, upper
panel), which is characteristic for ER-retained AQP2 proteins
(30), whereas wt-AQP2 was only detected as a 29-kD band. At
higher expression levels (10 ng cRNA), however, complex-
glycosylated (40 to 45 kD; wt-AQP2 and AQP2-V168M) and
a 27-kD degradation product (AQP2-V168M, AQP2-T126M)
were detected as well.
Immunoblotting of plasma membranes of these oocytes re-
vealed a clear plasma membrane expression for wt-AQP2 and
AQP2-V168M at every injected amount, whereas AQP2-
T126M was not detected in the plasma membranes (Figure 3,
middle panel). To relate the plasma membrane and total mem-
brane expression levels, total membranes equivalents of 1-, 3-,
and 10-ng injections were treated with endoglycosidase F,
which removes all sugar moieties, and immunoblotted for
AQP2 (Figure 3, lower panel). The immunoblot signals were
densitometrically scanned and semiquantified by comparison
with the immunoblot signals obtained from a twofold dilution
series of wt-AQP2 (data not shown). As reported, a decreased
ratio of plasma membrane versus total membrane expression
for an AQP2 mutant compared with that of wt-AQP2 indicates
that the mutant protein is retained within the cell (38).
As can be seen in Figure 3, AQP2-V168M showed a reduced
plasma membrane versus total membrane ratio than wt-AQP2
(e.g., compare signals of 3 ng AQP2-V168M to 10 ng wt-
AQP2). Densitometric analysis revealed a fourfold reduced
plasma membrane expression of AQP2-V168M compared with
wt-AQP2. Compared with AQP2-T126M, however, the traf-
ficking of AQP2-V168M to the plasma membrane was much
better because the total membrane expression level from 3 ng
AQP2-T126M cRNA was in between those of 1 and 3 ng
AQP2-V168M (Figure 3, bottom), whereas no plasma mem-
brane expression was detected for AQP2-T126M, in contrast to
that of oocytes injected with 1 ng AQP2-V168M cRNA. This
indicated that AQP2-V168M is impaired in its transport to the
membrane compared with wt-AQP2, but that its trafficking to
the plasma membrane is significantly better than of AQP2-
T126M. Determining the conferred water permeabilities (Fig-
ure 2) for similar plasma membrane expression levels of wt-
AQP2 and AQP2-V168M revealed that the ability of AQP2-
V168M to confer water permeation is about 58% of that of
wt-AQP2.
Immunocytochemical analysis of these oocytes showed a
dispersed intracellular expression for AQP2-V168M and
AQP2-T126M, although AQP2-V168M also revealed a weak
plasma membrane expression (Figure 4, A and B), which is
Figure 3. Immunoblot analysis of aquaporin-2 (AQP2)–V168M ex-
pressed in oocytes. From 12 oocytes, injected as described in Figure
2, total membranes (top) or plasma membranes (middle) were isolated
and immunoblotted for AQP2. Total membrane samples were also
immunoblotted for AQP2 after removal of all sugar moieties with
endoglycosidase F (bottom). The masses of unglycosylated (29 kD),
high-mannose glycosylated (32 kD), complex-glycosylated (40 to 45
kD), and a degradation product (27 kD) are indicated.
Figure 4. Localization of aquaporin-2 (AQP2)–V168M in oocytes.
Two days after injection, uninjected oocytes (D) and oocytes injected
with 1 ng cRNA encoding AQP2-V168M (A), wt-AQP2 (C), or 3 ng
for AQP2-T126M (B) were fixed in paraformaldehyde and embedded
in paraffin; 5-m sections were cut and incubated with rabbit -AQP2
antibodies, followed by Alexa-594.
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consistent with ER retention for both mutants and a partial
plasma membrane expression of AQP2-V168M. As antici-
pated, wt-AQP2 was only detected in the plasma membrane
(Figure 4C). Uninjected oocytes, which were taken as controls,
did not show any staining (Figure 4D), confirming the speci-
ficity of the AQP2 antibodies.
Effect of the Mutation on Aquaporin-2 Function on
Water Excretion and dDAVP Response
Family members who were homozygous for the mutation
(III-3, III-5, and III-7) had a mean 24-h urinary volume of
10,542  941 ml and mean Uosm of 69  9 mOsm/kg (Table
1). The mean 24-h urine volume of the family members het-
erozygous for the mutation (II-2 and III-9) was 1500  0 ml,
which was similar to spousal controls (III-4 and III-6) 1275 
530 ml (P  0.66). The mean Uosm in the heterozygotes was
648  41 mOsm/kg, also similar to the controls (641  257
mOsm/kg; P  0.96).
Two homozygous (III-5 and III-7) and one heterozygous
(II-2) family members participated in the water deprivation
study (Table 2 and Figure 5). All of the baseline electrolytes,
blood urea nitrogen, glucose, creatinine, and calcium levels
were within normal limits. After the Sosm reached 300 mOsm/
kg, and 2 h after 1 g of dDAVP was provided intravenously,
the homozygotes had Uosm of 146 mOsm/kg and 216 mOsm/
kg. The urine volume did not decrease after the dose of
dDAVP. In III-7, the mean urine volume before dDAVP was
417  40 ml/h, and the mean post-dDAVP treatment was 720
 113 ml/h (P  0.14). In III-5, the urine volumes were 625
 240 ml/h and 700  283 ml/h (P  0.78) before and after
dDAVP, respectively. The 2-h Uosm in the heterozygote sub-
ject was 521 mOsm/kg, consistent with partial NDI. Only one
of the homozygous individuals (III-5) had high levels of AVP
(29.6 pg/ml) at the maximum Sosm of 320 mOsm/kg.
Three homozygous (III-3, III-5, and III-7), two heterozygous
(II-2 and III-9), and two control (III-4 and III-6) family mem-
bers participated in the dDAVP challenge test (Table 3 and
Figure 6). Baseline electrolytes, blood urea nitrogen, glucose,
creatinine, and calcium levels were within normal limits. The
father (II-2) had elevated systolic and diastolic BP, with means
of 152  12 mm Hg and 79  6 mm Hg, respectively. In the
homozygous individuals, the mean Uosm was 70  3
mOsm/kg at baseline, 116  16 mOsm/kg after the first dose,
and 173  15 mOsm/kg after the second dose of dDAVP. In
these same individuals, the water intake had decreased, with a
mean intake of 252  131 ml/h between the first and second
dose of dDAVP and 199  143 ml/h between the second and
third dose of dDAVP (P  0.07). The mean urine volume did
not decrease significantly between the first and second dose of
dDAVP (P  0.81).
The heterozygous individuals had a baseline urinary osmo-
lality of 762  274 mOsm/kg, which was not significantly
different from 697  34 mOsm/kg observed in controls (P 
0.76). Similarly, the results of the urinary osmolality after the
first dose of dDAVP between the heterozygotes (874  247
mOsm/kg) and controls (803  46 mOsm/kg) were not signif-
icantly different (P  0.78). One of the controls and one of the
heterozygous required only one dose of dDAVP of 1 g to
increase urine osmolarity above 800 mOsm/kg.
Genetic Studies of the Mexican Town
Buccal cell samples were collected from 222 individuals
from the town of origin of the family. We evaluated DNA from
218 of the samples. We were unable to evaluate four samples
(2%) because of poor DNA harvest. Fifty-nine percent of the
samples were from women, and 41% were from men. The
mean age of the individuals sampled was 48  20 yr (women,
48  19 yr; men, 49  20 yr). The age distribution of the
sample had a preponderance of older individuals when com-
pared with the Mexican estate where the town is located, the
Nuevo Leon estate (Figure 7). Of the total 218 samples pro-
cessed, 151 samples (69%) did not have the V168M mutation
in AQP2. Sixty-five samples (30%) were heterozygous for the
V168M AQP2 mutation, and two samples (1%) were homozy-
gous for the mutation. The C/T polymorphism immediately
adjacent to the mutation was also observed in this population at
a frequency of 8% T allele. The polymorphism did not asso-
ciate with the mutation and was in Hardy-Weinberg
equilibrium.
The gender distribution of the group heterozygous for the
mutation was similar to the sample: 63% women and 37%
men. The mean age of the individuals heterozygous for the
V168M was 59 yr  20, 11  0 yr older than the sample (P 
0.01). The two homozygous individuals were both women, 25
and 60 yr of age. Deviation from Hardy-Weinberg equilibrium
for the V168M polymorphism was evaluated, and the popula-
tion was found not to deviate significantly from the expectation
on the basis of the marginal genotype frequencies (2 3.094,
P  0.080).
Discussion
We have characterized a V168M mutation in AQP2 in a
family with recessive NDI from Mexico. This mutation caused
a partial defect in the affected individuals. No previous AQP2
Table 1. Results of 24-h urine collection
Individuals
M/M V/M V/V
III-7 III-5 III-3 III-9 II-2 III-6 III-4
Urine volume (ml/24 h) 11,600 9800 10,225 1500 1500 1650 900
Hourly volume (ml) 483 408 426 63 63 69 38
Uosm (mOsm/kg) 62 66 80 583 712 459 822
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mutation has been described in individuals of Mexican or Latin
American ethnic origin, although five Brazilian families of
European ancestors were reported with AQP2 mutations (15).
The V168M mutation in AQP2 has been described in a family
of European descent, in which clinically affected individuals
were compound heterozygotes for the V168M and a S126P
mutation (16). The functional effect of the V168M mutation on
AQP2 was not previously studied, as opposed to the S216P
mutation (3,4). The studies in oocytes and the immunocyto-
chemistry results revealed that AQP2-V168M was retained in
the ER, a molecular defect that is common with AQP2 mutants
causing recessive NDI (30). However, compared with AQP2-
T126M, which is another mutant in recessive NDI, AQP2-
V168M is clearly less impaired in its trafficking to the plasma
membrane, because even at lower total membrane expression
levels, more AQP2-V168M is detected in the plasma mem-
brane (Figures 3 and 4). Because it is well known that an
impaired exit from the ER is a consequence of misfolding and
retention by molecular chaperones that exert the ER quality
control, this reduced level of ER retention of AQP2-V168M
compared with AQP2-T126M might indicate that AQP2-
168M is less misfolded than AQP2-T126M. This is under-
scored by the single channel permeability of about 58% for
AQP2-V168M in relation to wt-AQP2, whereas 20% was
found for AQP2-T126M (36). Our oocyte studies do not
reveal whether AQP2-V168M mRNA and protein are less
stable than of AQP2-T126M. However, if these stabilities are
similar in vivo, the observed differences in permeability and
trafficking to the plasma membrane of these AQP2 mutants
would provide a cell biologic explanation for the partial im-
provement of the urinary concentrating capacity and thirst
reduction with the use of dDAVP in the AQP2-V168M indi-
viduals and the absence of any increased urine-concentrating
ability with dDAVP in the NDI patients encoding AQP2-
T126M (14).
Only homozygous individuals in the family were clinically
affected with partial NDI, a finding based on very high 24-h
urine volumes and low urinary osmolalities in the NDI range,
even after water deprivation and administration of dDAVP.
The baseline AVP levels were lower than expected for patients
with severe NDI. In addition, during the water deprivation and
saline infusion, the AVP levels only increased outside the
normal range for the Sosm in III-5, in whom the second AVP
drawn was 29.6 pg/ml for a Sosm of 320 mOsm/kg, supporting
the possibility of a milder type of disease.
Family members heterozygous for the AQP2 mutation (II-2
and III-9) were not clinically affected and had Uosm and urine
volumes similar to those of controls. The father (II-2), 55 yr
Table 2. Results of water deprivation testa
Saline Infusion After 1 g dDAVP
Baseline 1h 2h 3h 1h 2h
III 7 (M/M)
UOsm (mOsm/kg) 65 85 98 0 130 146
Sosm (mOsm/kg) 304 304 307 0 310 317
UVol (ml/h) 410 380 460 640 800
AVP (pg/ml) 4.2 3.9
III5 (M/M)
UOsm (mOsm/kg) 76 110 142 185 224 216
Sosm (mOsm/kg) 291 294 309 321 323 316
UVol (ml/h) 400 450 750 900 900 500
AVP (pg/ml) 2.9 29.6
II/2 (V/M)
UOsm (mOsm/kg) 404 412 493 508 502 521
Sosm (mOsm/kg) 289 297 298 307 311 309
Uvol (ml/h) 120 110 120 110 220 180
AVP (pg/ml) 1.0 2.8
a Uosm, urine osmolality; Sosm, serum osmolality; Uvol, urine volume; AVP, vasopressin.
Figure 5. Results of the water deprivation test in three family
members.
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old, showed partial NDI in two separate tests with a maximal
urine osmolarity of 699 mOsm/Kg, when a normal 80-yr-old
individual should be able to reach at least a urinary osmolality
of 823 mOsm/Kg (22,24,29). It is possible that he had limited
urinary concentrating capacity as a result of other causes, such
as long-standing hypertension.
Usually NDI does not respond to treatment with dDAVP
unless some vasopressin and AQP2 activity remains at the
kidney level (39). Because of the rarity of this mutation, we
had no families with other mutations available to be used as
controls. The majority of the subjects with AQP2 mutations did
not respond to dDAVP (3,4,11–13,15,16). Three previous stud-
ies in patients with AQP2 mutations have demonstrated partial
diabetes insipidus, one individual with an autosomal recessive
mutation (9) and the other two individuals with autosomal
dominant mutations (17,20). AVPR2 mutations have also been
reported to produce partial response to dDAVP with milder
phenotypes and with mothers affected with partial NDI
(15,16).
The homozygotes in our study repeatedly reported subjec-
tive improvement of thirst and urination when dDAVP was
used at home, as expected if principal collecting duct cells are
still responding demonstrating some AQP2 function. This was
confirmed by the oocyte functional studies and the clinical
studies. The Uosm increased marginally with water deprivation
and dDAVP, and some functional aquaporin-2 was found in
the plasma membrane of the oocytes. The urinary output in
homozygotes treated with dDAVP or water deprivation was
Table 3. dDAVP challenge testa
M/M V/M V/V
III-7 III-5 III-3 III-9 II-2 III-6 III-4
Uosm base (mOsm/kg) 69 73 67 956 568 721 673
Sosm base (mOsm/kg) 294 293 289 296 294 296 285
First dDAVP dose (mcg) 5 5 5 1 1 1 1
fluid intake (ml/h) 240 128 388 145 261 118 307
urine volume (cc) 1800 600 1552 125 516 200 452
urine output (ml/h) 450 150 388 31 129 50 113
Uosm (mOsm/kg) 109 135 105 1049 699 770 835
Second dDAVP dose (g) 36.3 19.4 24 None 4 4 None
fluid intake (ml/h) 160 80 358 110 163
urine volume (cc) 500 725 1434 225 180
urine output (ml/h) 167 242 478 75 60
Uosm (mOsm/kg) 179 183 156 692 956
Sosm (mOsm/kg) 301 303 297 291 296
a Uosm, urine osmolality; Sosm, serum osmolality.
Figure 6. Results of the dDAVP (1-desamino-8-D-arginine-vasopres-
sin) challenge test in affected and unaffected family members.
Figure 7. Age distribution of the sample collected in the Mexican
town compared with the XII Censo General de Poblacion y Vivienda
(Nuevo Leon) 2000 Census.
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not significantly changed, but a decrease in their water intake
was observed during the dDAVP challenge test.
None of the affected individuals in the Mexican family had
mental or developmental abnormalities despite symptoms of
polyuria and polydipsia from an early age. In addition, two
undiagnosed affected individuals were identified in the Mexi-
can town. These results indicate that some AQP2 mutations
causing partial recessive NDI permits normal growth and men-
tal development, even if the disease is undiagnosed. Members
of other large kindreds affected with NDI have reported mental
retardation or failure to thrive as a result of untreated NDI. In
a family with recessive AQP2 mutations, 6 of 11 individuals
had slow psychomotor development or mental retardation and
short stature (2). Another study reported the death of three
children with symptoms of diabetes insipidus in a family with
recessive AQP2 gene mutations (4). None of the affected
individuals in the Mexican family had mental or developmental
abnormalities, despite symptoms of polyuria and polydipsia
from an early age. In addition, two undiagnosed affected indi-
viduals were identified in the Mexican town.
The fact that each of the parents of the proband carried the
same rare recessive AQP2 mutation led us to do a genetic
epidemiologic study in the town of origin. The population
sampled in the town was older when compared with the na-
tional census. In addition, more women than men were sam-
pled. Young men in the town were often employed as seasonal
migrant farm workers, and this fact may have affected the
population sampled. Thirty percent of the individuals in the
sample were heterozygous for the mutation, and 1% were
homozygous. The frequency of individuals affected by muta-
tions in the AQP2 gene in the general population of Mexico is
unknown, but it is likely to be less than one in a million (8,40).
The high frequency of the mutant allele in the population
(15.8%) suggests a founder effect of the mutation in the pop-
ulation. The extraordinarily high prevalence of this recessive
mutation in the town, along with the distribution of the muta-
tion along all ages, suggests a relatively high risk of having
more affected individuals born in this town. The heterozygote
individuals had a similar gender distribution when compared
with the entire sample, but had a mean age 11 yr older, which
could be suggestive of increased admixture with other popu-
lations in the younger generations.
The polymorphism immediately adjacent to the mutation
was clearly in equilibrium and was on a separate allele from the
mutation. None of the individuals in the family had the poly-
morphism at nucleotide 501 present in their DNA. In addition,
none of the individuals in the town that were homozygous for
the polymorphism had the mutation. The health care workers
in the town were previously unaware of the presence of NDI in
the community. The life-threatening complications of NDI can
be easily treated if an individual and the health care providers
are aware of the condition. As an attempt to increase the
alertness in the town about the disease, we have provided
medical information concerning this condition to the health
care workers and the population.
Conclusion
In summary, individuals affected with partial NDI in a
family of Mexican origin were found to be homozygous for a
V168M mutation in AQP2. Consistent with this phenotype,
AQP2-V168M was retained in the ER of oocytes, but was still
partially functional and less impaired in its trafficking to the
cell surface than another functional AQP2 mutant involved in
severe recessive NDI. The affected homozygous individuals
reported subjective improvement of thirst and urination with
the use of dDAVP. This finding was consistent with the clin-
ical studies, which showed partial NDI. dDAVP treatment
partially increased Uosm and decreased fluid intake. Heterozy-
gotes compared with controls showed no urinary concentrating
defects. In the genetic epidemiologic study of the town of
origin, we found a high prevalence of the V168M mutation,
suggesting a founder effect. The mutation in the population
was in Hardy-Weinberg equilibrium. Affected individuals had
no neurologic deficits from untreated NDI. This raises the
speculation that undiagnosed cases of NDI may exist in other
populations. Preventive and educational measures were imple-
mented in the town with the cooperation of the local health
authorities.
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